New China FDA chief signals pricing reform a priority

A change at the top of China FDA may indicate that drug pricing reform is now a top priority of the government.

China State Council Deputy Secretary-General Bi Jingquan will serve as both CFDA commissioner and secretary-general of the Communist Party, a

Read the full 425 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE